Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP569991.RAFnZ7Csh_P2dW28FTkC1SYVEEt64HaYsrZ5ntmgdNYdU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP569991.RAFnZ7Csh_P2dW28FTkC1SYVEEt64HaYsrZ5ntmgdNYdU130_assertion type Assertion NP569991.RAFnZ7Csh_P2dW28FTkC1SYVEEt64HaYsrZ5ntmgdNYdU130_head.
- NP569991.RAFnZ7Csh_P2dW28FTkC1SYVEEt64HaYsrZ5ntmgdNYdU130_assertion description "[We investigated the possible involvement of several molecules, including c-ABL, platelet-derived growth factor receptor (PDGFR), cellular FADD-like interleukin-1 alpha-converting enzyme-like inhibitory protein (c-FLIP)(L/S), Fas-associated DD kinase, p53, p21(WAF1), proteins of B-cell leukemia/lymphoma 2 (Bcl-2) family and cytochrome c. Imatinib did not modulate the expression or activation of its own targets, such as c-ABL, PDGFRalpha and PDGFRbeta, but it did affect the expression of c-FLIP(L), BCL2-associated X protein (Bax) and Bcl-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP569991.RAFnZ7Csh_P2dW28FTkC1SYVEEt64HaYsrZ5ntmgdNYdU130_provenance.
- NP569991.RAFnZ7Csh_P2dW28FTkC1SYVEEt64HaYsrZ5ntmgdNYdU130_assertion evidence source_evidence_literature NP569991.RAFnZ7Csh_P2dW28FTkC1SYVEEt64HaYsrZ5ntmgdNYdU130_provenance.
- NP569991.RAFnZ7Csh_P2dW28FTkC1SYVEEt64HaYsrZ5ntmgdNYdU130_assertion SIO_000772 16983347 NP569991.RAFnZ7Csh_P2dW28FTkC1SYVEEt64HaYsrZ5ntmgdNYdU130_provenance.
- NP569991.RAFnZ7Csh_P2dW28FTkC1SYVEEt64HaYsrZ5ntmgdNYdU130_assertion wasDerivedFrom befree-2016 NP569991.RAFnZ7Csh_P2dW28FTkC1SYVEEt64HaYsrZ5ntmgdNYdU130_provenance.
- NP569991.RAFnZ7Csh_P2dW28FTkC1SYVEEt64HaYsrZ5ntmgdNYdU130_assertion wasGeneratedBy ECO_0000203 NP569991.RAFnZ7Csh_P2dW28FTkC1SYVEEt64HaYsrZ5ntmgdNYdU130_provenance.